La vendita allo scoperto per Nabriva Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Nabriva Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Nabriva Therapeutics (OTC:NBRVF) Azioni, Report sulle vendite allo scoperto

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

NABRIVA THERAPEUTICS NEW by Nabriva Therapeutics plc

Nabriva Therapeutics PLC

LightPath Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTH#NASDAQ">LPTH</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.05) by 80 percent. This is a 28.57 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $9.17 million which beat the analyst consensus estimate of $8.78 million by 4.37 percent. This is a 19.08 percent increase over sales of $7.70 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

LPTH

LightPath Technologies Q3 EPS $(0.09) Misses $(0.05) Estimate, Sales $9.17M Beat $8.78M Estimate

Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) reported quarterly losses of $(0.47) per share. This is a 14.63 percent decrease over losses of $(0.41) per share from the same period last year.

PHIO

Phio Pharma Q1 EPS $(0.47) Down From $(0.41) YoY

Airship AI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AISP#NASDAQ">AISP</a>) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $(0.04) by 1625 percent. This is a 143.57 percent increase over losses of $(1.40) per share from the same period last year. The company reported quarterly sales of $5.50 million which beat the analyst consensus estimate of $4.30 million by 27.98 percent. This is a 47.96 percent decrease over sales of $10.57 million the same period last year.

AISP

Airship AI Holdings Q1 EPS $0.61 Beats $(0.04) Estimate, Sales $5.50M Beat $4.30M Estimate

General

SHOT

Safety Shot On May 9 Entered Securities Purchase Agreement For Purchase Of 641,000 Shares For Gross Proceeds Of $250,000

Seaport Global analyst Daniel Mckenzie maintains United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) with a Buy and lowers the price target from $103 to $89.

Price Target

Analyst Ratings

Seaport Global Maintains Buy on United Airlines Holdings, Lowers Price Target to $89

Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) has outperformed the market over the past 5 years by 11.39% on an annualized basis producing an average annual return of 26.51%. Currently, Live Nation Entertainment has a market capitalization of $34.11 billion. 
Buying $100 In LYV: If an investor had bought $100 of LYV stock 5 years ago, it would be worth $315.10 today based on a price of $145.70 for LYV at the time of writing.
<h3>Live Nation Entertainment's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747341913_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Live Nation Entertainment 5 Years Ago Would Be Worth This Much Today

Doximity Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>), which operates an online networking service for medical professionals, reported fiscal fourth-quarter financial results after the market close on Thursday. Shares appear to be moving lower due to weak guidance. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/b45450785/doximity-announces-fourth-quarter-and-fiscal-year-2025-financial-results">of the report</a>.
<ul class="wp-block-list">
<li>Q4 Revenue: $138.29 million, versus <a href="http://benzinga.com/quote/docs/earnings">estimates</a> of $133.73 million</li>
</ul>
<ul class="wp-block-list">
<li>Q4 Adjusted EPS: 31 cents, versus estimates of 27 cents</li>
</ul>
Total revenue climbed 17% year-over-year. Subscription revenue was also up 17%, totaling $131.9 million in the quarter. The company reported operating cash flow of $98.5 million and free cash flow of $97 million for the fourth quarter.
Doximity ended the quarter with approximately $209.61 million in cash and cash equivalents.
&#8220;We closed out fiscal 2025 on a high note, with record engagement, strong profits, and 20% annual revenue growth,&#8221; said Jeff Tangney, co-founder and CEO of Doximity. &#8220;Our newsfeed, workflow and AI tools all hit fresh highs in the fourth quarter, helping doctors save time and provide the best care for their patients.&#8221;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45453142/meta-platforms-stock-dips-on-ai-rollout-delay-amid-internal-turmoil-report">Meta Platforms Stock Dips On AI Rollout Delay Amid Internal Turmoil: Report</a>
Outlook: Doximity guided for fiscal first-quarter revenue of $139 million to $140 million versus estimates of $143.34 million, according to Benzinga Pro. The company also forecasted full-year 2026 revenue of $619 million to $631 million versus estimates of $634.6 million.
Doximity executives will further discuss the quarter on a call with investors and analysts at 5 p.m. ET.
DOCS Price Action: <a href="http://benzinga.com/quote/docs">Doximity shares</a> were down 24.48% in Thursday&#8217;s after-hours session, trading at $45.02 at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Doximity.

Guidance

Health Care

Movers

DOCS

Doximity Stock Dives On Q4 Earnings As Guidance Comes In Below Estimates

Jet AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) reported quarterly losses of $(1.85) per share which missed the analyst consensus estimate of $(1.31) by 41.22 percent. This is a 97.11 percent increase over losses of $(64.08) per share from the same period last year. The company reported quarterly sales of $3.47 million which missed the analyst consensus estimate of $3.90 million by 10.93 percent. This is a 9.73 percent decrease over sales of $3.85 million the same period last year.

JTAI

Jet AI Q1 EPS $(1.85) Misses $(1.31) Estimate, Sales $3.47M Miss $3.90M Estimate

Air Industries (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIRI#AMEX">AIRI</a>) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.04) by 575 percent. This is a 28.57 percent decrease over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $12.13 million which missed the analyst consensus estimate of $14.00 million by 13.32 percent. This is a 13.70 percent decrease over sales of $14.06 million the same period last year.

AIRI

Air Industries Q1 EPS $(0.27) Misses $(0.04) Estimate, Sales $12.13M Miss $14.00M Estimate

Falcons Beyond Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBYD#NASDAQ">FBYD</a>) reported quarterly losses of $(0.13) per share. This is a 110.2 percent decrease over earnings of $1.27 per share from the same period last year. The company reported $1.71 million in sales this quarter. This is a 12.66 percent increase over sales of $1.52 million the same period last year.

FBYD

Falcons Beyond Global Q1 EPS $(0.13) Down From $1.27 YoY, Sales $1.71M Up From $1.52M YoY

Signing Day Sports Q1 EPS $(0.44) Up From $(7.68) YoY, Sales $148.36K Down From $234.63K YoY

Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) reported quarterly losses of $(0.35) per share. This is a 75 percent increase over losses of $(1.40) per share from the same period last year. The company reported $238.49 thousand in sales this quarter. This is a 77.29 percent decrease over sales of $1.05 million the same period last year.

SIDU

Sidus Space Q1 EPS $(0.35) Up From $(1.40) YoY, Sales $238.49K Down From $1.05M YoY

BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) reported quarterly losses of $(0.16) per share. This is a 50 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $1.61 million which beat the analyst consensus estimate of $1.30 million by 23.62 percent. This is a 26.32 percent decrease over sales of $2.18 million the same period last year.

BKYI

BIO-key Intl Q1 EPS $(0.16) Up From $(0.32) YoY, Sales $1.61M Beat $1.30M Estimate

A trade war between China and the United States, involving President Donald Trump&#8217;s higher tariff prices, could be hurting the nation&#8217;s favorability rating. 
A new survey shows that net favorability for China has surpassed the United States for the first time since polling began in 2020.
What Happened: A new Morning Consult poll shows China ranking ahead of the U.S. for net favorability as of early April, <a href="https://www.benzinga.com/news/global/25/04/44620889/trumps-liberation-day-tariffs-roil-markets-as-china-slams-typical-unilateral-bullying-asian-markets-plunge">when </a><a href="https://www.benzinga.com/news/global/25/04/44620889/trumps-liberation-day-tariffs-roil-markets-as-china-slams-typical-unilateral-bullying-asian-markets-plunge" target="_blank" rel="noopener">Trump announced the </a>so-called Liberation Day, declaring tariff amounts on numerous countries worldwide. According to recent surveys, net favorability ratings have remained with China ahead for the month of April.
Morning Consult has <a href="https://pro.morningconsult.com/analysis/us-china-global-standing-competition">polled </a>residents in dozens of countries, 41 in the latest survey, over the years.
Countries included in the core data since 2020 include the United States, China, Australia, Brazil, Canada, France, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain and the United Kingdom. Ratings from a person's own country are removed from the rankings.
A <a href="https://x.com/cameron_easley/status/1922645080826847484" target="_blank" rel="noopener">chart </a>shows that the gap between China and the U.S. has increased since the 2024 election. This suggests that Trump&#8217;s win may have increased negative views of the U.S. by residents of other countries and/or China&#8217;s favorable ratings may have improved over the same period.
Trump's inauguration and quick tariff announcements worsened the United States&#8217; favorability rating.
At the start of 2025, 29 of the 41 core countries in the survey viewed the U.S. as more favorable than China. As of April 30, only 13 of the 41 countries favor the United States over China.
The net favorability rating for the United States appears to have improved after the recent 90-day reciprocal tariff pause between China and America, which will be closely monitored going forward to see if the U.S. can repass China.
Read Also:<a href="https://www.benzinga.com/trading-ideas/25/05/45144516/trump-a-grinch-or-santa-for-christmas-children-will-have-two-dolls-instead-of-30-dolls"> Trump A Grinch Or Santa For Christmas? &#8216;Children Will Have Two Dolls Instead Of 30 Dolls&#8217;</a>
 Why It's Important: Trump's approval rating has fallen in many polls in 2025, including a<a href="https://www.benzinga.com/25/05/45256510/exclusive-trumps-approval-rating-drops-in-reader-survey-after-100-days-could-stock-market-be-to-blame"> Benzinga reader poll</a> showing his approval rating at the 100-day mark lower than it was during his first 52 days in office.
One factor that could be hurting Trump's approval ratings and the country&#8217;s net favorability rating is the stock market returns, which have been impacted by tariffs.
The stock market indexes and stocks have fallen on tariff news, while items like the 90-day pause announcement have sent shares higher and put the S&amp;P 500 back in the green in 2025.
Trump's first 100 days in office saw the worst return for the S&amp;P 500 at the start of a four-year term since Richard Nixon in 1973. The S&amp;P 500 was down 7.8% in Trump's first 100 days, trailing the 9.9% drop in Nixon's first 100 days.
For comparison, the S&amp;P 500 has an average return of 2.1% in the first 100 days of a presidency, dating back to 1944.
While U.S. stocks have been hurt in 2025, Chinese stocks and ETFs have mostly outperformed.
Here's a look at the year-to-date returns of some of the top Chinese ETFs by assets under management:
<ul class="wp-block-list">
<li>KraneShares Trust China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>): +19.3%</li>
<li>iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>): +19.6%</li>
<li>iShares MSCI China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHI#NASDAQ">MCHI</a>): +18.5%</li>
</ul>
Compare that to the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which are up 0.9% and 1.6%, respectively, on a year-to-date basis.
While stock market performance is only one factor, it would appear that the new presidency and tariffs are among the reasons other countries view the United States less favorably than China.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/04/45069781/trumps-first-100-days-what-he-delivered-where-he-fell-short-how-markets-reacted">Trump&#8217;s First 100 Days: What He Delivered, Where He Fell Short, How Markets Reacted</a></li>
</ul>
Photo: Shutterstock

Politics

Global

KWEB

MCHI

China Tops US In Global Favorability After 'Liberation Day,'  Trump Tariffs Blamed For International Image Slide

Management

Sensata Technologies CFO Brian Roberts To Resign, Andrew Lynch Appointed Interim CFO Effective May 16

New Concept Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GBR#AMEX">GBR</a>) reported quarterly losses of $(0.01) per share. This is a 200 percent decrease over earnings of $0.01 per share from the same period last year. The company reported $38.00 thousand in sales this quarter. This is a 5.56 percent increase over sales of $36.00 thousand the same period last year.

New Concept Energy Q1 EPS $(0.01) Down From $0.01 YoY, Sales $38.00K Up From $36.00K YoY

NVFY

Nova Lifestyle Q1 EPS $(0.03) Up From $(0.65) YoY, Sales $2.63M Up From $2.38M YoY

Beam Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEEM#NASDAQ">BEEM</a>) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.23) by 39.13 percent. The company reported $6.324 million in sales this quarter. This is a 56.57 percent decrease over sales of $14.561 million the same period last year.

BEEM

Beam Glb Q1 2025 Adj. EPS $(0.32) Misses $(0.23) Estimate, Sales $6.324M Down From $14.561M YoY

CAVA Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) reported first-quarter financial results after the market close on Thursday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/b45451578/cava-group-reports-first-quarter-2025-results">of the report</a>.
Q1 Earnings: Cava's first-quarter revenue increased 28.2% year-over-year to $331.83 million, beating the <a href="http://benzinga.com/quote/CAVA/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a> of $326.88 million, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The Mediterranean fast-casual restaurant chain company reported first-quarter adjusted earnings of 22 cents per share, beating analyst estimates of 14 cents per share.
The company noted that net income included an income tax benefit of $10.7 million related to equity-based compensation.
Cava&nbsp;reported the same restaurant sales growth&nbsp;of 10.8% and traffic growth of 7.5%. The company said it opened 15 new restaurants during the quarter, bringing total locations up to 382, up 18.3% year-over-year.
Net cash provided by operating activities totaled $38.6 million and free cash flow came in at $2.7 million in the quarter. The company ended the period with $289.35 million in cash and cash equivalents.
&#8220;In spite of economic uncertainty and challenging weather, CAVA&#8217;s&nbsp;first quarter&nbsp;results demonstrate the continued strength of our category-defining brand,&#8221; said&nbsp;Brett Schulman, co-founder and CEO of Cava Group.
Guidance: Cava expects full-year same-restaurant sales growth to be between 6% and 8%, unchanged from prior guidance. The company expects to open between 64 and 68 new restaurants in total this year, up from prior guidance of 62 to 66 restaurants.
Cava&#8217;s management team will hold a conference call with investors and analysts to further discuss the quarter at 5 p.m. ET.
CAVA Price Action: <a href="https://www.benzinga.com/quote/CAVA" target="_blank" rel="noreferrer noopener">Cava shares</a> were down 4.10% in after-hours, trading at $95 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/insights/news/25/05/45395034/heres-how-much-you-would-have-made-owning-chipotle-mexican-grill-stock-in-the-last-15-years">Here&#8217;s How Much You Would Have Made Owning Chipotle Mexican Grill Stock In The Last 15 Years</a></li>
</ul>
Photo: courtesy of Cava Group.

Restaurants

After-Hours Center

CAVA

Cava Group Reports Q1 Earnings: Revenue Jumps 28%, Company Bumps Up New Restaurant Openings Guidance

Milestone Scientific (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#AMEX">MLSS</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. This is unchanged from the same period last year. The company reported quarterly sales of $2.23 million which missed the analyst consensus estimate of $2.43 million by 8.32 percent. This is a 0.76 percent decrease over sales of $2.25 million the same period last year.

Comments

Nabriva Therapeutics

Vendite allo scoperto

Nabriva Therapeutics (OTC:NBRVF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO